Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.

Autor: Cascone T; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kar G; AstraZeneca, Translational Medicine, Research and Early Development, Oncology Research and Development, Cambridge, United Kingdom., Spicer JD; Department of Thoracic Surgery, McGill University, Montreal, Quebec, Canada., García-Campelo R; Medical Oncology Unit, University Hospital A Coruña, A Coruña, Spain., Weder W; Thoracic Surgery, Clinic Bethanien, Zurich, Switzerland., Daniel DB; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee., Spigel DR; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee., Hussein M; Sarah Cannon Research Institute, Florida Cancer Specialists, Leesburg, Florida., Mazieres J; Thoracic Oncology Department, Toulouse University Hospital, Toulouse, France., Oliveira J; Medical Oncology Department, Portuguese Oncology Institute (IPO-PORTO), Porto, Portugal., Yau EH; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York., Spira AI; Virginia Cancer Specialists, US Oncology Research, NEXT Oncology Virginia, Fairfax, Virginia., Anagnostou V; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland., Mager R; AstraZeneca, Gaithersburg, Maryland., Hamid O; AstraZeneca, Gaithersburg, Maryland., Cheng LY; AstraZeneca, Gaithersburg, Maryland., Zheng Y; AstraZeneca, Gaithersburg, Maryland., Blando J; AstraZeneca, Gaithersburg, Maryland., Tan TH; AstraZeneca, Munich, Germany., Surace M; AstraZeneca, Gaithersburg, Maryland., Rodriguez-Canales J; AstraZeneca, Gaithersburg, Maryland., Gopalakrishnan V; AstraZeneca, Gaithersburg, Maryland., Sellman BR; AstraZeneca, Gaithersburg, Maryland., Grenga I; AstraZeneca, Waltham, Massachusetts., Soo-Hoo Y; AstraZeneca, Gaithersburg, Maryland., Kumar R; AstraZeneca, Gaithersburg, Maryland., McGrath L; AstraZeneca, Waltham, Massachusetts., Forde PM; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.

Publikováno v: Cancer discovery [Cancer Discov] 2023 Nov 01; Vol. 13 (11), pp. 2394-2411.

P2.04-03 EGRET: First-in-human Study of the Novel Antibody-drug Conjugate AZD9592 ± Anti-cancer Agents in Advanced Solid Tumours

Autor: Aggarwal, C., Solomon, B., Spira, A., Massarelli, E., Lau, S.C.m., Le, X., Rolfo, C., Planchard, D., Felip, E., Wu, Y.-L., Ahn, M.-J., Goto, K., Azaro, A., Lissa, D., Hamid, O., McGrath, L., Maudsley, R., Hayward, C., Mathewson, A., Arnaldez, F., Grenga, I., Azzoli, C.

Publikováno v: In Journal of Thoracic Oncology November 2023 18(11) Supplement:S306-S306

929MO Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study

Autor: Spicer, J., Cascone, T., Kar, G., Zheng, Y., Blando, J., Tan, T.H., Cheng, M., Mager, R., Hamid, O., Soo-Hoo, Y., Forde, P.M., Weder, W., Garcia Campelo, M.R., Grenga, I., Kumar, R., McGrath, L.

Publikováno v: In Annals of Oncology September 2022 33 Supplement 7:S971-S971

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges.

Autor: Ye, Yunyao¹ (AUTHOR) yeyunyao20230419@njmu.edu.cn, Yu, Shanxun¹ (AUTHOR) 15720803282@163.com, Guo, Ting² (AUTHOR) guoting20230419@njmu.edu.cn, Zhang, Sihui¹ (AUTHOR) zhangshtaizhou@163.com, Shen, Xiaozhou¹ (AUTHOR) kevinsxz@163.com, Han, Gaohua¹ (AUTHOR) danny_75@njmu.edu.cn

Publikováno v: Biomolecules (2218-273X). Dec2024, Vol. 14 Issue 12, p1523. 19p.